Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

Two Neds—Ned David and Ned Sharpless—form Jupiter Bioventures and close $70M in initial financing

Jupiter Bioventures, a biotechnology venture foundry that builds science-driven therapeutics companies, announced the closing of a $70 million initial financing.

November 22, 2024

Vol.50 No.44

In Brief

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

LSU Health New Orleans was awarded a five-year, $3.1 million grant from the National Institute of Dental and Craniofacial Research.

November 15, 2024

Vol.50 No.43

In Brief

Mayo Clinic, IgniteData collaborate to deploy data transfer platform

IgniteData announced a collaboration with Mayo Clinic to deploy its Archer platform across multiple sites in the U.S., aiming to improve the management of clinical trial data by enhancing the transfer of information from Electronic Health Records to Electronic Data Capture systems.

October 25, 2024

Vol.50 No.40

Clinical

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

If clinical research were anything like fly fishing, the scientific question that EA3163 trial attempted to answer might be considered “the one that got away”.

SU2C announces grants supporting research in six cancer types

Stand Up To Cancer announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including head and neck, pediatric, pancreatic, breast, rectal, and gastro-esophageal cancers, as well as research focused on how the microbiome communicates with the immune system.

October 18, 2024

Vol.50 No.39

Clinical Roundup

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

The phase III KEYNOTE-689 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative treatment for patients newly diagnosed with stage 3 or 4A, resected, locally advanced head and neck squamous cell carcinoma met its primary endpoint of event-free survival.

October 11, 2024

Vol.50 No.38

Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

YOU MAY BE INTERESTED IN

Two Neds—Ned David and Ned Sharpless—form Jupiter Bioventures and close $70M in initial financing

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

Mayo Clinic, IgniteData collaborate to deploy data transfer platform

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

SU2C announces grants supporting research in six cancer types

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

Renew today!

Subscriber content

Never miss an issue!

Login